Jump Financial LLC Sells 1,960,263 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Jump Financial LLC trimmed its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 98.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 39,737 shares of the company's stock after selling 1,960,263 shares during the quarter. Jump Financial LLC's holdings in Ionis Pharmaceuticals were worth $1,389,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its holdings in shares of Ionis Pharmaceuticals by 967.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 141,917 shares of the company's stock worth $4,961,000 after acquiring an additional 128,619 shares during the period. SG Americas Securities LLC lifted its stake in Ionis Pharmaceuticals by 222.5% during the fourth quarter. SG Americas Securities LLC now owns 23,927 shares of the company's stock worth $836,000 after purchasing an additional 16,508 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Ionis Pharmaceuticals by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company's stock valued at $763,000 after purchasing an additional 373 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 11.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,994 shares of the company's stock valued at $384,000 after purchasing an additional 1,101 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth $829,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Price Performance

Shares of Ionis Pharmaceuticals stock traded up $0.45 on Thursday, reaching $29.55. The stock had a trading volume of 1,180,248 shares, compared to its average volume of 1,524,994. The business's 50 day moving average is $30.75 and its two-hundred day moving average is $34.04. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. The company has a market cap of $4.70 billion, a P/E ratio of -9.72 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a 1 year low of $23.95 and a 1 year high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The firm's quarterly revenue was down 30.2% on a year-over-year basis. During the same quarter last year, the company earned $0.12 earnings per share. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on IONS shares. Redburn Atlantic started coverage on Ionis Pharmaceuticals in a research note on Monday, March 31st. They issued a "neutral" rating and a $39.00 price objective on the stock. Citigroup dropped their price objective on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Royal Bank of Canada reiterated an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. HC Wainwright began coverage on Ionis Pharmaceuticals in a research report on Monday, April 7th. They set a "buy" rating and a $45.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their target price on Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating for the company in a research report on Monday, March 24th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $56.72.

Insider Buying and Selling

In other news, EVP Patrick R. O'neil sold 1,207 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the sale, the executive vice president now owns 56,245 shares of the company's stock, valued at approximately $1,819,525.75. The trade was a 2.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Swayze sold 1,367 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $32.31, for a total value of $44,167.77. Following the transaction, the executive vice president now owns 48,017 shares in the company, valued at approximately $1,551,429.27. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,167 shares of company stock worth $2,010,458 in the last quarter. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.